Use of human prostate cell lines in cancer treatment

Abstract

This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the mammal or human afflicted with cancer to mount an attack against the tumour lesion. In particular, the invention pertains to the use of whole-cells, derivatives and portions thereof with or without vaccine adjuvants and/or other accessory factors. More particularly, this disclosure describes the use of particular combinations of whole-cells and derivatives and portions thereof that form the basis of treatment strategy.

1 - 23 . (canceled) 
     
     
         24 . A method of prophylaxis or treatment of prostate cancer, comprising administering to a patient one or more doses of an immunogenic agent comprising three different allogeneic human prostate cell lines, wherein the cell lines are derived from tissues selected from the group consisting of:
 (a) normal, non-cancerous human prostate tissue,   (b) primary, non-metastasized human prostate cancer tissue, and   (c) metastasized human prostate cancer tissue,   
       wherein at least one cell line is an immortalized normal, non-cancerous cell line. 
     
     
         25 . The method of  claim 24 , wherein the immunogenic agent comprises two cell lines derived from tumor tissues. 
     
     
         26 . The method of  claim 24 , wherein the immunogenic agent comprises two cell lines derived from normal tissue. 
     
     
         27 . The method of  claim 24 , wherein the immunogenic agent comprises the cell-lines PNT2 (ECACC 95012613), NIH-1542 (ATCC CRL-12037), and LNCap (ATCC CRL-1740). 
     
     
         28 . The method of  claim 24 , wherein the immunogenic agent comprises the cell-lines PNT2, NIH1542 and DU145 (ATCC HTB-81). 
     
     
         29 . The method of  claim 24 , wherein the immunogenic agent comprises the cell-lines PNT2, DU145 and LnCAP. 
     
     
         30 . The method of  claim 24 , wherein the immunogenic agent comprises a physiologically
 acceptable agent selected from the group consisting of an excipient, an adjuvant and a carrier.   
     
     
         31 . The method of  claim 24 , wherein the immunogenic agent comprises vaccine adjuvant selected from the group consisting of BCG,  M. Vaccae , Tetanus toxoid, Diphtheria toxoid,  Bordetella Pertussis , interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and a non-specific adjuvant. 
     
     
         32 . The method of  claim 24 , wherein the immunogenic agent comprises a vaccine adjuvant which is a mycobacterial preparation. 
     
     
         33 . The method of  claim 24 , wherein the immunogenic agent induces an immune response in patients characterized by activation of immune T-cells. 
     
     
         34 . The method of  claim 24 , wherein the immunogenic agent induces an immune response in patients characterized by induction of antibody production. 
     
     
         35 . The method of  claim 24 , wherein the immunogenic agent induces a decrease in the rate of rise or a decline in the level of serum PSA in prostate cancer patients. 
     
     
         36 . The method of  claim 24 , wherein the immunogenic agent is administered intradermally. 
     
     
         37 . The method of  claim 24 , wherein the immunogenic agent is administered intraprostatically. 
     
     
         38 . The method of  claim 24 , comprising administering at least 4 doses. 
     
     
         39 . The method of  claim 24 , comprising administering 4 to 6 doses over a period of 16 weeks. 
     
     
         40 . A method of inducing an immune response against prostate cancer cells, comprising administering to a patient one or more doses of an immunogenic agent comprising three different allogeneic human prostate cell lines, wherein the cell lines are derived from tissues selected from the group consisting of:
 (d) normal, non-cancerous human prostate tissue,   (e) primary, non-metastasized human prostate cancer tissue, and   (f) metastasized human prostate cancer tissue,   
       wherein at least one cell line is an immortalized normal, non-cancerous cell line. 
     
     
         41 . The method of  claim 40 , wherein the immunogenic agent comprises two cell lines derived from tumor tissues. 
     
     
         42 . The method of  claim 40 , wherein the immunogenic agent comprises two cell lines derived from normal tissue. 
     
     
         43 . The method of  claim 40 , wherein the immunogenic agent comprises the cell-lines PNT2, NIH-1542 and LNCap. 
     
     
         44 . The method of  claim 40 , wherein the immunogenic agent comprises the cell-lines PNT2, NIH1542 and DU145. 
     
     
         45 . The method of  claim 40 , wherein the immunogenic agent comprises the cell-lines PNT2, DU145 and LnCAP. 
     
     
         46 . The method of  claim 40 , wherein the immunogenic agent comprises a physiologically acceptable agent selected from the group consisting of an excipient, an adjuvant and a carrier. 
     
     
         47 . The method of  claim 40 , wherein the immunogenic agent comprises vaccine adjuvant selected from the group consisting of BCG,  M. Vaccae , Tetanus toxoid, Diphtheria toxoid,  Bordetella Pertussis , interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and a non-specific adjuvant. 
     
     
         48 . The method of  claim 40 , wherein the immunogenic agent comprises a vaccine adjuvant which is a mycobacterial preparation. 
     
     
         49 . The method of  claim 40 , wherein the immunogenic agent induces an immune response in patients characterized by activation of immune T-cells. 
     
     
         50 . The method of  claim 40 , wherein the immunogenic agent induces an immune response in patients characterized by induction of antibody production. 
     
     
         51 . The method of  claim 40 , wherein the immunogenic agent induces a decrease in the rate of rise or a decline in the level of serum PSA in prostate cancer patients. 
     
     
         52 . The method of  claim 40 , wherein the immunogenic agent is administered intradermally. 
     
     
         53 . The method of  claim 40 , wherein the immunogenic agent is administered intra-prostatically. 
     
     
         54 . The method of  claim 40 , comprising administering at least 4 doses. 
     
     
         55 . The method of  claim 40 , comprising administering 4 to 6 doses over a period of 16 weeks.